Altimmune Earnings Call Transcripts
Fiscal Year 2026
-
Management emphasized strategic progress, financial strength, and differentiation of pemvidutide in the evolving MASH/NASH market. Phase III trials are set to begin enrollment in the second half of the year, with a readout expected in 2029. Expansion into AUD and ALD is underway, with key data readouts and updates anticipated next quarter.
-
Phase III enrollment for pemvidutide in MASH is set for later this year, supported by strong EASL data and robust funding. The program leverages AI tools and flexible endpoints, aiming for differentiation in a growing market, with phase II AUD data expected soon.
-
Raised $225M in April, boosting cash to $535M and securing runway through 2029. Advancing pemvidutide with phase III MASH trial to start H2 2026, phase II AUD data due next quarter, and strong focus on tolerability and efficacy to differentiate in a competitive market.
-
The meeting covered director elections, auditor ratification, executive compensation, and amendments to share authorization and employee stock plans. All proposals passed by majority or plurality vote, with results to be filed with the SEC.
-
Phase II data for pemvidutide in MASH showed strong resolution and anti-fibrotic effects, supporting a differentiated phase III design with AI-assisted histology. Progress continues in AUD and ALD trials, with financial and leadership enhancements positioning for late-stage success.
-
Recent clinical data show pemvidutide offers strong efficacy, tolerability, and a unique dual mechanism for MASH, with phase III trials designed for robust endpoints and regulatory flexibility. Ongoing studies in alcohol-related indications may further expand its therapeutic reach.
-
Pemvidutide is advancing toward a phase III trial in MASH, supported by strong phase II data on MASH resolution, weight loss, and tolerability. Its unique one-to-one glucagon/GLP-1 ratio and commercial strategy aim to address key unmet needs, with a solid financial runway into 2028.
Fiscal Year 2025
-
Pemvidutide advanced with strong phase 2b MASH results, FDA Breakthrough Therapy designation, and a robust cash position supporting a global phase 3 trial in 2026. Market research shows high physician interest, and additional phase 2 trials in AUD and ALD are progressing.
-
IMPACT phase 2b 48-week data for pemvidutide in MASH showed significant, dose-dependent improvements in fibrosis markers, liver fat, and weight loss, with a strong safety and tolerability profile. Regulatory alignment with the FDA supports a phase 3 program using both 1.8 mg and 2.4 mg doses and innovative AI pathology tools.
-
A leadership transition is underway as the company prepares for phase III trials and commercialization, with two major catalysts—an FDA meeting and 48-week data—expected by year-end. Flexible trial design, strong clinical results, and expansion into AUD and ALD position the company for growth.
-
A dual GLP-1/glucagon agonist is advancing for MASH, AUD, and ALD, showing strong efficacy and tolerability in early trials. Phase three planning is underway, with flexibility for regulatory changes and a focus on both liver and metabolic benefits.
-
Pemvidutide, a balanced glucagon/GLP-1 dual agonist, demonstrated rapid MASH resolution, strong anti-fibrotic activity, and quality weight loss in 24-week data, with 48-week results expected soon. The program is well-positioned for regulatory flexibility and expansion into AUD and ALD, supported by strong tolerability and financial resources.
-
Pemvidutide showed strong anti-fibrotic and weight loss effects in MASH, with robust financials and flexible phase three planning. Rapid trial enrollment and positive market feedback highlight significant commercial potential across MASH, AUD, and ALD.
-
The conference highlighted pemvidutide’s strong phase IIb results in MASH, with robust efficacy, best-in-class tolerability, and a unique dual mechanism. Flexible trial design and upcoming regulatory milestones position it well for phase III and commercial success.
-
Phase II data showed rapid, robust MASH resolution, weight loss, and strong tolerability, with AI and NITs supporting efficacy. The phase III trial is designed for regulatory flexibility, and the drug’s dual-action profile positions it strongly in a growing MASH market.
-
The meeting covered director elections, auditor ratification, executive compensation, and governance matters. All proposals passed by majority or plurality vote, and no shareholder questions were submitted.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is showing class-leading efficacy and tolerability in NASH, with robust weight loss and anti-inflammatory effects. Regulatory strategy leverages non-invasive endpoints, and the drug is being advanced for NASH, obesity, AUD, and ALD, with key data and FDA meetings expected in Q4.
-
Pemvidutide, a dual GLP-1/glucagon agonist, demonstrated class-leading MASH resolution and rapid liver fat reduction at 24 weeks, with strong non-invasive test results and high physician interest. Regulatory acceptance of computer-based reads and NITs is advancing.
-
Pemvidutide achieved significant efficacy and safety in MASH at 24 weeks, with strong financials and a strategic shift toward phase III and commercialization. Full 48-week data and key FDA meetings are expected in Q4, with ongoing trials in AUD and ALD.
-
The phase II-B Impact Trial of Pemvidutide in MASH achieved up to 59.1% MASH resolution at 24 weeks, significant weight loss, and strong safety with minimal discontinuation. AI and non-invasive tests showed promising anti-fibrotic activity, supporting high potential for phase III success.
-
Pemvidutide’s dual mechanism targets both obesity and liver disease, positioning it as a differentiated MASH therapy. The phase II trial is robustly designed, with endpoints in weight loss, MASH resolution, and fibrosis improvement, and is supported by strong financials and strategic flexibility.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is advancing in MASH, AUD, and ALD with a unique 24-week readout and strong efficacy in weight loss, liver fat reduction, and lipid improvement. The strategy targets high unmet needs in liver diseases, with multiple phase II and III milestones expected soon.
-
IMPACT phase 2b MASH trial data is expected this quarter, with pemvidutide positioned as a potential first-in-class therapy combining rapid MASH resolution and weight loss. Financially, cash reserves rose to $150 million, bolstered by a new $100 million credit facility, supporting expanded clinical programs in MASH, AUD, and ALD.
-
Pemvidutide, a GLP-1/glucagon dual agonist, is advancing in a well-powered phase IIb trial for MASH, showing strong efficacy in liver fat reduction, weight loss, and safety. Top-line data are expected in Q2, with a solid cash position supporting further development and expansion into new liver indications.
-
Pemvidutide is advancing in obesity, MASH, AUD, and ALD, with phase II trials for AUD and ALD launching in 2025 and a pivotal MASH readout expected in Q2 2025. Strong clinical data, regulatory support, and a robust cash position underpin plans for independent commercialization in liver indications and a partnership for obesity.
-
Pemvidutide, a dual GLP-1/glucagon agonist, is advancing in both MASH and obesity with strong efficacy, safety, and tolerability. Phase II-B trials show class-leading liver fat reduction, weight loss, and lean mass preservation, with phase III programs and partnerships planned.
-
Pemvidutide, a dual GLP-1/glucagon agonist, showed strong efficacy in obesity and MASH, with significant weight loss, liver fat reduction, and lean mass preservation. The ongoing Phase IIb MASH trial is expected to deliver a first-of-its-kind 24-week readout, and further indications are in development.
Fiscal Year 2024
-
Significant progress in 2024 included completion of Phase 2b enrollment for pembedutide in MASH, FDA clearance for two new indications, and a strong cash position funding operations into 2026. Top-line IMPACT trial data is expected in Q2 2025, with Phase 3 initiation planned for early 2026.
-
Key 2025 milestones include a phase 2b MASH readout and up to three new INDs, with a focus on leveraging glucagon's unique benefits for liver and lipid metabolism. The program is differentiated by strong weight loss effects, a favorable safety profile, and rapid regulatory progress.
-
Pemvidutide, a balanced GLP-1/glucagon dual agonist, is advancing in both obesity and MASH with strong safety and efficacy signals, including muscle preservation and lipid improvements. Phase 3 trials are underway, with key MASH data expected in Q2 next year.
-
Pemvidutide, a GLP-1/glucagon dual agonist, shows strong efficacy in weight loss, liver fat reduction, and lipid improvement, with a favorable safety profile and FDA support for pivotal trials. The company is advancing MASH independently, seeking a partner for obesity, and planning new indications.
-
Key milestones include full enrollment of the phase 2b IMPACT trial in MASH, FDA alignment on a comprehensive phase 3 obesity program, and a strong cash position funding operations into 2026. Pemvidutide’s unique profile and new indications drive strategic growth and partnership interest.
-
Pemvidutide’s phase III VELOCITY program targets weight loss and key comorbidities with a unique GLP-1/glucagon profile, supported by strong phase II results and FDA endorsement. The upcoming phase IIb MASH data in 2Q25 and a differentiated safety/tolerability profile position it as a potential class leader.
-
Pemvidutide, a dual GLP-1/glucagon agonist, shows rapid and robust effects on weight loss, liver fat, and serum lipids, with a unique safety profile and muscle preservation. Phase IIb MASH trial readout is expected in Q2 next year, with commercialization targeted for 2028 in obesity and 2030 in MASH.
-
Pemvidutide showed strong weight loss and lean mass preservation in obesity trials, with significant lipid and liver fat reductions, supporting its differentiation in metabolic disease. Cash reserves fund operations into 2026, with key MASH data expected in Q1 2025.
-
Pemvidutide, a GLP-1/glucagon dual agonist, demonstrated strong weight loss, lipid, and liver fat reduction with best-in-class lean mass preservation and tolerability. Phase IIb MASH data is expected in Q1 next year, with strategic focus on regulatory engagement, partnerships, and market differentiation.
-
Pemvidutide, a GLP-1/glucagon dual agonist, is advancing toward phase III for obesity and NASH, with strong biomarker and clinical data supporting its differentiation and efficacy. Partnership discussions are ongoing, and pivotal NASH biopsy data are expected in Q1 next year.